The randomised trial of 52 weeks was conducted in 11 countries and included over 500 patients, Lupin said.

Here is a list of top stocks that are likely to take focus in today's trading session.

Take a look at top stocks that are likely to stay in limelight in today's trading.

Lupin's Etanercept biosimilar, developed by its Biotechnology Research Group in Pune will be the first product to be licensed for clinical ...